CN103263435A - 聚维酮碘的新用途 - Google Patents
聚维酮碘的新用途 Download PDFInfo
- Publication number
- CN103263435A CN103263435A CN2013101833944A CN201310183394A CN103263435A CN 103263435 A CN103263435 A CN 103263435A CN 2013101833944 A CN2013101833944 A CN 2013101833944A CN 201310183394 A CN201310183394 A CN 201310183394A CN 103263435 A CN103263435 A CN 103263435A
- Authority
- CN
- China
- Prior art keywords
- povidone iodine
- group
- treatment
- disinfectant
- ielt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229920000153 Povidone-iodine Polymers 0.000 title claims abstract description 23
- 229960001621 povidone-iodine Drugs 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 24
- 206010036596 premature ejaculation Diseases 0.000 claims abstract description 18
- 239000000645 desinfectant Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 3
- 229940035535 iodophors Drugs 0.000 claims description 11
- 230000000694 effects Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 229960002073 sertraline Drugs 0.000 description 12
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 12
- 239000000890 drug combination Substances 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 238000007086 side reaction Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241001069921 Libido Species 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 229940066875 sertraline 25 mg Drugs 0.000 description 1
- 229940071981 sertraline 50 mg Drugs 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种聚维酮碘在制备用于治疗早泄药物中的用途，所述药物为聚维酮碘与其他生物学中任一相适配的载体形成的组合物，例如聚维酮碘消毒剂或安多福PVP-I消毒剂。其有益效果是：通过实验证明聚维酮碘可以提高患者ILET，对于早泄病人具有明显治疗效果。
Description
技术领域
本发明涉及医药技术领域，特别涉及一种聚维酮碘的新用途。
背景技术
早泄是年轻男性最常出现的性功能障碍，在成年男性中的发病率为21-33%。目前对于早泄主要有手术治疗和口服药物两种，其中，对于早泄的推荐药物为5-羟色胺再摄取抑制剂（SSRIs），其代表性药物是舍曲林和帕罗西汀，其作用机制是通过抑制突触前膜5-HT的再摄取部位，提高突触间隙5-HT浓度，达到延迟射精的目的。从临床研究看，该类药物对于早泄具有一定治疗作用，但是该类药物副作用极为明显，容易出现程度不同的副反应，包括嗜睡、烦躁、磨牙、恶心等，停药2-3天后，副反应消失，对于肾功衰等患者，是否可以应用此类药物，尚无报道。因此，目前市场上尚没有对于早泄效果明确的外用药物。
发明内容
本发明的主要目的在于，针对上述现有技术中的不足，提供一种聚维酮碘的新用途。
本发明解决现有技术问题所采用的技术方案是：聚维酮碘在制备用于治疗早泄药物中的用途。
所述药物为聚维酮碘与其他生物学中任一相适配的载体形成的组合物。
所述药物为聚维酮碘消毒剂或安多福PVP-I消毒剂。
所述药物为外用制剂，直接涂抹于冠状沟上下1.5-2cm位置。
本发明的有益效果是：通过实验证明聚维酮碘可以提高患者ILET，对于早泄病人具有明显治疗效果。
附图说明
图1为治疗前后31个人的ILET散点图；
图2为治疗前后组a（舍曲林单用）ILET散点图；
图3为治疗前后组b（安多福PVP-I消毒剂单用）ILET散点图；
图4为治疗前后组c（联合用药）ILET散点图；
本发明目的的实现、功能特点及优点将结合实施例，参照附图做进一步说明。
具体实施方式
以下将结合附图及具体实验例详细说明本发明的技术方案，以便更清楚、直观地理解本发明的发明实质。
实验例
1、实验对象：
31名早泄患者，年龄（27±5）岁，早泄时间0.5-2年，进行本实验前放弃其他治疗1月以上，所有患者性欲正常，无吸毒史、无可疑药物使用、放射物质接触史，其中包皮环切手术史10例，肾功能不全1例，婚后性生活不成功2例，勃起不坚1例。
2、检测标准：
以阴道内射精潜伏时间（intravaginal ejaculation latency time,IELT）为检测参数，插入阴道后时间不足1分钟，按照1分钟计算，治疗前后分别取3次IELT，计算平均值。
3、实验方法：
采用a、b、c三组进行实验，其中，
a组采用常用早泄的推荐药物舍曲林单用，口服，舍曲林50mg，QN，16-21天；b组采用安多福PVP-I消毒剂（以聚维酮碘为主要成分）单用，涂抹于冠状沟上下1.5-2cm位置，QN，7-8天，安多福PVP-I消毒剂为深圳市安多福消毒高科技股份有限公司生产；组c采用舍曲林与安多福PVP-I消毒剂联合用药，舍曲林25mg，QN，安多福PVP-I消毒剂用法同上，应用时间7-8天。分别于用药后1月计算IELT。
4、实验结果：
4.1采用spss18.0计算各组数据IELT，具体结果见表1：
表1为治疗前与治疗后IELT一览表，其中，角码1表示治疗前IELT，角码2表示治疗后IELT，例如A1表示治疗前的IELT，A2表示治疗后的IELT，N表示人数。
4.2参照图1至图4所示，以治疗时间做散点图，从图1可以知道，治疗前较治疗后，时间上移，仅有一个数据重合，即31个人中，30个人的IELT时间均延长，仅有一个人的IELT时间未延长（IELT时间未延长的人为b组（安多福PVP-I消毒剂单用）中的某个人），而从图2可以看出，使用舍曲林的a组中4个人IELT时间均得到延长，从图3可以看出，使用安多福PVP-I消毒剂的b组中13个人中的12个人IELT时间均得到延长，仅有1个人未延长，从图4中可以看出，联合使用舍曲林和安多福PVP-I消毒剂的c组中14个均得到延长。
4.3统计分析
对所有数据进行统计学分析，采用SPSS18.0统计软件，对单变量采用t检验，检验水准取α=0.05，，检验结果如下：组类代码，a,b,c表示组别，后一组数据代表治疗时间，1代表治疗前时间，2代表治疗后时间，N代表人数。
表2为各组治疗前后IELT配对t检验结果：
表3组a与组b治疗前、治疗后IELT检验结果
表4组a与组c治疗前、治疗后IELT t检验结果
表5组b与组c治疗前、治疗后IELT t检验结果
5、结论：
聚维酮碘是临床常用的消毒剂，广泛应用于皮肤、粘膜的消毒，本次研究发现，该类药物对于早泄有明显疗效。
从散点图1-4可知，与治疗前相比较，治疗后患者IELT提高，在31名患者中，仅有1人IELT重合，治疗效果不明显。
从组内统计学结果来看（表2），治疗前后，在0.05水平，a组、b组、c组IELT存在统计学差异，治疗后较治疗前，IELT明显延长。
在治疗组之间的对比中（表3-5），在0.05水平，治疗前各组间无统计学差异，说明组间无统计学差异。在治疗后，a组与c组间存在统计学差异，说明联合用药组可能优于舍曲林单用组；b组与c组间无统计学差异，说明联合用药组与聚维酮碘单用组无统计学差异。推测，联合用药优于单独舍曲林单用组，联合用药与聚维酮碘单用组效果接近。
早泄是最常见的男性性功能障碍，在成年男性中的发病率为21-33%。目前对于早泄的推荐药物为5-羟色胺再摄取抑制剂（SSRIs），其代表性药物是舍曲林和帕罗西汀，本次研究选用了舍曲林，主要从其治疗效果和价格考虑。其作用机制是通过抑制突触前膜5-HT的再摄取部位，提高突触间隙5-HT浓度，达到延迟射精的目的。从临床研究看，该类药物对于早泄具有一定治疗作用。但是该类药物副作用极为明显，在本次研究中，5人出现程度不同的副反应，包括嗜睡、烦躁、磨牙、恶心等，停药2-3天后，副反应消失。对于肾功衰等患者，是否可以应用此类药物，尚无报道。
聚维酮碘恰好避免了该类药物的不足，从目前的用药情况看，尚无患者出现副反应或者不良反应。
从本次研究的实验数据看，联合用药优于舍曲林单用组，联合用药与聚维酮碘效果接近。说明聚维酮碘可以有效降低舍曲林用药剂量，单独应用聚维酮碘可以有效提高患者ILET，对于早泄病人具有明显治疗效果。
以上所述仅为本发明的优选实施例，并非因此限制其专利范围，凡是利用本发明说明书及附图内容所作的等效结构或等效流程变换，直接或间接运用在其他相关的技术领域，均同理包括在本发明的专利保护范围内。
Claims (4)
1.聚维酮碘在制备用于治疗早泄药物中的用途。
2.根据权利要求1所述的用途，其特征在于：所述药物为聚维酮碘与其他生物学中任一相适配的载体形成的组合物。
3.根据权利要求2述的用途，其特征在于：所述药物为聚维酮碘消毒剂或安多福PVP-I消毒剂。
4.根据权利要求1所述的用途，其特征在于：所述药物为外用制剂，直接涂抹于冠状沟上下1.5-2cm位置。
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310183394.4A CN103263435B (zh) | 2013-05-17 | 2013-05-17 | 聚维酮碘的制药用途 |
| PCT/CN2013/077499 WO2014183314A1 (zh) | 2013-05-17 | 2013-06-19 | 聚维酮碘的新用途 |
| JP2015551100A JP6028107B2 (ja) | 2013-05-17 | 2013-06-19 | ポビドンヨードの新たな用途 |
| US14/377,830 US20150023904A1 (en) | 2013-05-17 | 2013-06-19 | New application of pvp-i |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310183394.4A CN103263435B (zh) | 2013-05-17 | 2013-05-17 | 聚维酮碘的制药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103263435A true CN103263435A (zh) | 2013-08-28 |
| CN103263435B CN103263435B (zh) | 2014-08-13 |
Family
ID=49007131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310183394.4A Active CN103263435B (zh) | 2013-05-17 | 2013-05-17 | 聚维酮碘的制药用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20150023904A1 (zh) |
| JP (1) | JP6028107B2 (zh) |
| CN (1) | CN103263435B (zh) |
| WO (1) | WO2014183314A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180209781A1 (en) * | 2017-01-23 | 2018-07-26 | General Electric Company | Method of Making a Component with an Integral Strain Indicator |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1435210A (zh) * | 2002-01-28 | 2003-08-13 | 郑州市金阳保健品有限公司 | 中药皮肤消毒液及其在抑制男性早泄方面的应用 |
| CN1491647A (zh) * | 2002-10-22 | 2004-04-28 | 刘小兵 | 经皮式用于治疗阳痿和女性性冷淡并防治性病的组合物 |
| WO2006109190A1 (en) * | 2005-02-02 | 2006-10-19 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Tetracyclic monoamine reuptake inhibitors for treatment of cns diseases and disorders |
| CN101657101A (zh) * | 2007-02-12 | 2010-02-24 | Dmi生物科学公司 | 并存早泄和勃起功能障碍的治疗 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6447717A (en) * | 1987-08-17 | 1989-02-22 | Buhei Akaha | Infectious disease preventing drug |
| US5244096A (en) * | 1988-04-22 | 1993-09-14 | Stoner Fred L | Preventive treatment kit against sexually transmitted disease |
| CN1236619A (zh) * | 1998-05-27 | 1999-12-01 | 武汉迪普生物技术有限公司 | 一种新型的避孕药 |
-
2013
- 2013-05-17 CN CN201310183394.4A patent/CN103263435B/zh active Active
- 2013-06-19 JP JP2015551100A patent/JP6028107B2/ja active Active
- 2013-06-19 WO PCT/CN2013/077499 patent/WO2014183314A1/zh active Application Filing
- 2013-06-19 US US14/377,830 patent/US20150023904A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1435210A (zh) * | 2002-01-28 | 2003-08-13 | 郑州市金阳保健品有限公司 | 中药皮肤消毒液及其在抑制男性早泄方面的应用 |
| CN1491647A (zh) * | 2002-10-22 | 2004-04-28 | 刘小兵 | 经皮式用于治疗阳痿和女性性冷淡并防治性病的组合物 |
| WO2006109190A1 (en) * | 2005-02-02 | 2006-10-19 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Tetracyclic monoamine reuptake inhibitors for treatment of cns diseases and disorders |
| CN101657101A (zh) * | 2007-02-12 | 2010-02-24 | Dmi生物科学公司 | 并存早泄和勃起功能障碍的治疗 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150023904A1 (en) | 2015-01-22 |
| CN103263435B (zh) | 2014-08-13 |
| JP2016504372A (ja) | 2016-02-12 |
| JP6028107B2 (ja) | 2016-11-16 |
| WO2014183314A1 (zh) | 2014-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Becker et al. | Diagnosis, comorbidities, and management of restless legs syndrome | |
| Jermain et al. | Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study | |
| Santos-Alonso et al. | Pruritus in dialysis patients. Review and new perspectives | |
| Jokar et al. | The effect of magnesium sulfate on renal colic pain relief; a randomized clinical trial | |
| Furlani et al. | Sleep quality of women with gynecological and breast cancer | |
| JP2010530867A (ja) | うつ病の治療 | |
| Rhodin | The rise of opiophobia: is history a barrier to prescribing? | |
| Deka et al. | Persistent genital arousal disorder: Successful treatment with leuprolide (antiandrogen) | |
| Mazda et al. | Acupuncture for reducing pruritus induced by intrathecal morphine at elective cesarean delivery: a placebo-controlled, randomized, double-blind trial | |
| Almasi et al. | Doxepin | |
| CN103263435B (zh) | 聚维酮碘的制药用途 | |
| RU2009101026A (ru) | Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии | |
| Cho et al. | Perceptions of adequacy and job performance of nurse assistant nursing jobs according to registered nurses and nurse assistants in geriatric hospitals, and caregivers | |
| Hayhoe | Insomnia: can acupuncture help? | |
| Hoffman et al. | Effects of aerobic exercise on sexual functioning in depressed adults | |
| Chou et al. | Chronic Cotard's syndrome: Recovery from 2 years' bed-ridden status. | |
| Akpan et al. | A report of the ruinous effects of pentazocine abuse in a female adult with sickle cell anaemia seen in uyo, niger-delta region of nigeria: an urgent call to action | |
| Manjaly et al. | Potentially inappropriate medication use among elderly inpatients at a teaching hospital in South India | |
| Mikhael et al. | Intralesional pentoxifylline in the treatment of lepromatous ulcers | |
| Yang et al. | Effects of the expression of serum SIRT1 on therapeutic efficacy of sodium valproate in the treatment of epilepsy patients | |
| Davison | Pain Management in Chronic Kidney Disease | |
| Hofman | Practical steps to address pain in wound care. | |
| Buttle et al. | Massage for pain relief in pediatric palliative care: Potential benefits and challenges | |
| CN103301124B (zh) | 一种治疗癫痫的药物组合物 | |
| Wallace et al. | Open-label extension study on the long-term efficacy, safety, and impact on quality of life of OROS® hydromorphone extended release in patients with chronic low back pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |